Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CryoSave was a leading international stem cell bank specializing in the collection, processing, and cryopreservation of umbilical cord blood and cord tissue stem cells. Founded in 2000, the company operated in over 40 countries and was once the largest private cord blood bank in Europe, providing families with long-term storage for potential future therapeutic use. The company's services were designed to preserve neonatal stem cells for the treatment of various hematological, industrial, and genetic conditions. However, CryoSave faced significant financial and legal challenges, leading to its bankruptcy in 2019 and the subsequent transfer of its stored biological samples to the FamiCord Group (PBKM) in Poland.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CryoSave.